According to the World Health Organization (WHO), Cuban scientists in biotechnology have made a very important contribution to the development of new methods of prevention and treatment of cancer, aimed at transformation from a deadly disease into a chronic disease.

Overall, cancer cells are naturally present in the body of each person. They begin to pose a threat to life only when the immune system is unable to differentiate the cells of the healthy cells cancer. Therapy cancer treatment, immunotherapeutic stimulates the immune system of the body to fight against cancer cells, and makes it possible to control the current state. This type of cancer treatment used in Cuban hospitals, increases efficiency and reduces the toxicity of chemotherapy (chemotherapy), and radiotherapy. Treatment cancer in Cuba is so successful because of the unique medicines that produced Cuban medicine, for example - CIMAvax vaccine. Cuban Medical provides a complete program of treatment for cancer. Treatments are carried out at the National Institute of Oncology and Radiobiology (INOR) which have more than 50 years of successful experience in the treatment of cancer. The Cuban Institute cooperates closely with the Center for Molecular Immunology (CIM), which has developed a number of therapeutic vaccines for cancer, such as: CIMAher-Nimotuzumab, CIMAvax-EGF, VAKSIRA-Racotumomab, IOR EPOC IOR leukocytes etc.

Treatment for treating lung cancer

For the treatment of lung cancer, non-small cell, Cuban doctors have been developed two kinds of vaccines. CIMAvax and Vaxira. Based on the documentation of the patient, doctors decide which of the two vaccines is adequate to use and can bring better results. The aim of these vaccines is that cancer pupate and that the patient can live with as a chronic disease. CIMAVAX- monoclonal antibody vaccine EGFH-P64 / Montanid ISA 51 is a monoclonal antibody that has anti-tumor effect. It is a biological product with a therapeutic effect for improving the immune system of the patient, his quality of life and for control of the symptoms with encouraging results in patients in stages III and IV non-small lung cancer cells. Racotumomab (commercial name Vaxira®) is a therapeutic vaccine to be used in the treatment of solid tumors. It was developed by Racombia, public-private consortium which is made up of institutions from various countries, primarily by the Center of Molecular Immunology in Havana, Cuba, and researchers from the University of Buenos Aires and the National University of Quilmes, both from Argentina. It stimulates the immune system of the patient to create a response against a white molecule that is specific for cancer, with the aim of controlling the growth of tumors, slow the progression of the disease, and gradually extending the life of the patient. Recotumomab of stimulating an immune response against tumor antigens glycol N-GM3 (NGcGM3), of the gangliosides that are located on the surface of cancer cells, and lung cancer, breast cancer, melanoma and pediatric tumors of neuroektoderms.

Treatment for the treating cancer of the brain, head, colon and pancreas

For cancer of the brain, physicians have developed Cuban vaccine Nimotuzumab (CIMAher). Nimotuzumab HR3 is a humanized monoclonal antibody for treating cancer. It was developed at the Center of Molecular Immunology in Havana, Cuba. Nimotuzumab has the role of inclination between the environment and the high specificity of the extracellular regions of the EGFR (epidermal growth factor receptor). The increase in competition between ligand and receptor activation. Epidermal growth factor receptor EGFR is important factor in the development of cancer therapies. It proved to have a combination of Nimotuzumab Included with conventional treatments, such as radiation therapy and chemotherapy, gave a better response. HR3 is obtained by genetic engineering and the effect on the immune system so that it is activated, and it controls the growth of the tumor cells so as to compete with the proliferation of the factors with their receptor in the tumor cells, slowing down the growth rate of the same. Nimotuzumab in the research stage, and for other types of cancer, and proved to be successful, and in healing of the colon, and even in some cases of pancreas cancer.